Phase II trial of AMSA in prostatic cancer. 1982

R B Natale, and A Yagofa, and R C Watson

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000609 Aminoacridines Acridines which are substituted in any position by one or more amino groups or substituted amino groups.
D000677 Amsacrine An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent. m-AMSA,AMSA,AMSA P-D,Amsacrina,Amsidine,Amsidyl,Cain's Acridine,NSC-141549,NSC-156303,NSC-249992,SN-11841,SN11841,meta-AMSA,AMSA P D,AMSA PD,Cain Acridine,Cains Acridine,NSC 141549,NSC 156303,NSC 249992,NSC141549,NSC156303,NSC249992,SN 11841,meta AMSA
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

R B Natale, and A Yagofa, and R C Watson
February 1982, Cancer treatment reports,
R B Natale, and A Yagofa, and R C Watson
April 1983, Cancer treatment reports,
R B Natale, and A Yagofa, and R C Watson
November 1982, Cancer treatment reports,
R B Natale, and A Yagofa, and R C Watson
January 1981, Cancer chemotherapy and pharmacology,
R B Natale, and A Yagofa, and R C Watson
January 1981, Cancer treatment reports,
R B Natale, and A Yagofa, and R C Watson
March 1983, Cancer treatment reports,
R B Natale, and A Yagofa, and R C Watson
January 1981, Cancer clinical trials,
R B Natale, and A Yagofa, and R C Watson
August 1984, American journal of clinical oncology,
R B Natale, and A Yagofa, and R C Watson
January 1982, European journal of cancer & clinical oncology,
R B Natale, and A Yagofa, and R C Watson
April 1983, American journal of clinical oncology,
Copied contents to your clipboard!